$19.70
Value $684M
DCTH and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$19.70
Value $684M
$137.78
Value $341B
Delcath Systems (DCTH) has a market value of $684M and Merck & Company (MRK) $341B. Over the last year, with dividends, DCTH moved +128.8% and MRK +52.7%. The P/E is 102.9 for DCTH and 138.9 for MRK. Dividend yield: DCTH none, MRK 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
DCTH$684M
MRK$341B
MRK is 498 times DCTH
Revenue, 12 months
DCTH$110M
MRK$67.4B
MRK is 613 times DCTH
Net income, 12 months
DCTH$6.7M
MRK$2.5B
MRK is 369 times DCTH
Operating margin
DCTH5.2%
MRK–
ROIC
DCTH3.6%
MRK3.9%
0.3 points apart
P/E
DCTH102.9
MRK138.9
MRK is 1.3 times DCTH
Dividend yield
DCTH0.0%
MRK2.5%
2.5 points apart
5-year return
DCTH+97.2%
MRK+94.3%
2.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
DCTH+96.2%
MRK+94.3%
| Period | DCTHWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +128.8%Price +128.8% | +52.7%Price +48.4% |
| 3 years since November 17, 2023 | +704.1%+100.3% a yearPrice +704.1% | +48.4%+14.1% a yearPrice +35.4% |
| 5 years since November 17, 2021 | +97.2%+14.5% a yearPrice +97.2% | +94.3%+14.2% a yearPrice +66.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
DCTHDelcath SystemsMRKMerck & Company
| Price | $19.70 | $137.78 |
|---|---|---|
| Market value | $684M | $341B |
| Enterprise value (EV) | $580M | $385B |
| P/E | 102.9 | 138.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 5.1 | 7.6 |
| EV/EBIT | 102.0 | 80.8 |
| Free cash flow yield | 2.9% | 4.3% |
| Revenue, 12 months | $110M | $67.4B |
|---|---|---|
| Net income, 12 months | $6.7M | $2.5B |
| Free cash flow, 12 months | $20M | $14.7B |
| Earnings per share, 12 months | $0.19 | $0.98 |
| Revenue growth, year on year | 129.1% | 1.3% |
| Revenue growth a year, past | +121.3%over 4 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 87.6% | 71.8% |
|---|---|---|
| Operating margin | 5.2% | – |
| Net margin | 6.1% | 3.6% |
| ROIC | 3.6% | 3.9% |
| ROE | 5.6% | 5.2% |
| Cash | $104M | $9.7B |
|---|---|---|
| Total debt | $2.4M | $53.8B |
| Net debt / EBITDA | -17.6 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 0.9% | 1.5% |
| Shareholder yield | 0.9% | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($341B) is about 497.7 times Delcath Systems ($684M), at today's prices.
Since November 17, 2021, DCTH's price moved +97.2% and MRK's +66.8%. With dividends: DCTH +97.2% (+14.5% a year), MRK +94.3% (+14.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Delcath Systems and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 102.9 for DCTH and 138.9 for MRK. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 6.1% for Delcath Systems and 3.6% for Merck & Company, and the operating margin 5.2% and –. Revenue was $110M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.